Background and Objectives: Cell therapy provides an effective strategy for the treatment of an impaired liver. Human umbilical cord blood progenitor cells have the potential to differentiate into hepatocytes. Progenitor cells transplanted into the spleen could migrate directly into the liver through portal circulation. To track migration of human umbilical cord blood progenitor cells in cirrhotic rat liver after intrasplenic transplantation and to prove the possibility similar behavior of human umbilical cord blood nucleated cells in humans. Methods and Results: Umbilical cord blood samples from full-term deliveries will be collected after obtaining an informed consent from the mother. The collection procedure will be conducted after completion of delivery and will not interfere with the normal obstetric procedures. Adult male Sprague Dawley rats were subjected to liver cirrhosis by intraperitoneal injection of thioacetamide. Cirrhotic rats were treated with human umbilical cord blood nucleated cells by intra-splenic transplantation. Migration of intrasplenic transplanted human umbilical cord blood cells to the liver was successfully documented with Immunohistochemistry. The liver and spleen from recipient animals were removed. Histopathological and immunohistochemical analysis were performed 20 weeks after intrasplenic injection of the cells. Intrasplenically injected cells migrate to the liver of recipient animals. Conclusions: Human cord blood nucleated cells have the potential to differentiate into hepatocytes and substantially improve the histology and function of the cirrhotic liver in rats. Relocation into liver after intrasplenic transplantation could be detected by immunohistochemistry. Transdifferentiated cells could be efficiently stained with antihuman hepatocytes.
Introduction
Cell transplantation provides an effective strategy for the treatment of an impaired liver or liver failure. When compared with orthotopic liver transplantation, stem cell transplantation has the advantages of lower cost, lower risk, and simpler manipulation of the procedure. Autologous cell transplantation helps prevent immunologic re-jection, which is always a problem for orthotopic liver transplantation, and it bears great potential usefulness as a transient therapy before liver transplantation (1) .
Exploitation of high regeneration and differentiation of stem cells may solve this problem. Transdifferentiation of different kinds of stem cells into hepatocytes has been previously demonstrated with embryonic stem cells, hepatoblasts (mostly in fetal liver), hepatic oval cells (mostly in mature liver), pancreatic progenitor cells, bone marrow hematopoietic stem cells, and mesenchymal stem cells (MSCs) (2) (3) (4) (5) . Bone marrow-derived stem cells exhibited better prospects in terms of practical applicability as surrogates of hepatocytes for transplantation in MSCs. Both in vitro and in vivo, studies appeared to support bone MSCs (BMSCs) as being more potent in hepatocytic trans- bedded in paraffin. Tissue sections 4um thick were taken from each rat and organ. For histopathological examination, sections were stained with H&E as well as Masson trichrome stain for detection of fibrosis. To investigate the hepatic differentiation of cord blood cells injected into the spleen of cirrhotic rats and their liver engraftment, we traced UCB cells by immunostaining analysis with antihuman hepatocyte antibody (Clone OCHIE 5; DACO) as the primary antibody which reacts only with human hepatocytes but not with rat hepatocytes. The sections were deposited on charged glass slides. Slides were dried completely and deparaffinized and rehydrated in xylene and grades of alcohol, the slides were exposed to epitope retrieval by placing them in boiling water containing 0.01 ml/L sodium citrate buffer (PH6) for 15 min. Followed by quenching of endogenous peroxidase with 1% hydrogen peroxide (H202) for 10 minutes. The primary antibody was applied for 24h in humid chamber. The primary antibody was detected using ABC complex and developed with DAB as substrate the slides were counterstained with hematoxylin, mounted in DPX and covered with cover slips.
Results
In our study mortalities between animals during the induction of cirrhosis reached 60%. There was elevation of the liver enzymes and impairment of the synthetic functions of the liver represented by the significant decrease in serum albumin and the significant rise of total bilirubin and INR of cirrhotic; these results confirm the injurious effect of Thioacetamide on hepatocytes rats. Gross examination of livers retrieved after animal sacrifice showed yellow firm, shrunken liver with nodular surface, cut section showed yellow cirrhotic nodules. Histopathological examination revealed distorted architecture, ductular proliferation and regenerative parenchymatous nodules surrounded by fibrous connective tissue septa Fig. 1A . In this study, we injected nucleated cells derived from UCB into the spleen of immunocompetent rats after induction of cirrhosis without immunosupression. The histological sections didn't show significant inflammatory aggregates indicating that graft was not rejected. No apoptosis was detected indicating that implanted cells survived in the recipient tissues. Histopathologic examination also showed significantly decreased fibrosis and marked liver regeneration as well as better restoration of architecture as shown by H&E ( Fig. 1B) .
Liver sections of transplanted animals were stained positive for anti-human hepatocyte antibodies ( Fig. 2A-C) , which stains only human hepatocytes, while none of the control animals showed such staining (Fig. 2D ). Sections of spleens of the recipient animals showed no human hepatocytes by immunostaining ( Fig. 2E , F) indicating that UCBSCs had migrated to the liver and engrafted, multiplied and differentiated into human hepatocytes.
Discussion
Cell therapy can be defined as ≪the use of living cells to restore, maintain or enhance the function of tissues and organs≫ (32) .Such a therapeutic strategy was put forward as an alternative to orthotopic liver transplantation (OLT), which requires major surgery and is limited by the availability of donors. Indeed, it was shown that significant clinical results can be obtained with the transplantation of isolated hepatocytes corresponding to as little as 1-5% of the total hepatocyte mass (33) . The procedure seems relatively safe, provided portal pressure and/or portal flow are monitored during cell infusion in order to prevent vascular thrombosis (34) .
Hepatocyte transplantation has recently been used as an alternative to OLT in patients with liver-based congenital metabolic disorders, such as Crigler-Najjar disease, Alpha 1-antitrypsin deficiency, glycogen storage disease type Ia, Ornithine transcarbamoylase deficiency, and the deficiency of factor VII.
The main factor limiting the practice of hepatocyte transplantation is again the availability of liver grafts for cell isolation. Moreover, the metabolic effects of cell trans- plantation seem to be fading with time, a problem which can partially be solved by repeated hepatocyte infusions, but which probably indicates the progressive loss of the terminally-differentiated exogenous cells. In theory, both problems could be solved by replacing the hepatocyte with stem or precursor cells, provided they can be isolated from a more affordable source (35) .
Stem cells present in adult BM and UCB are undifferentiated long-lived cells that have the ability to proliferate extensively and maintain the ability to differentiate into multiple cell types including bone cells, cartilage cells, fat cells, tendon cells, muscle cells, marrow stromal cells, astrocytes, etc. Potential liver-cell progenitors have been identified from BM, peripheral blood, UCB, fetal liver, adult liver and embryonic stem cells (36). Stem cells are present in UCB and possess several typical traits. Clonal culture of fluorescence-activated cell sorter CD34＋ UCB and BM cells revealed a higher incidence of colony-forming cells with greater proliferation capacity in UCB than BM CD34＋ cells. UCB CD34＋ cells also demonstrated a higher secondary plating efficiency than BM cells. Rats transplanted with UCB mononuclear cells showed significantly higher levels of chimerism than those transplanted with BM mononuclear cells. Recipients of UCB transplants from HLA-identical siblings have a lower incidence of acute and chronic graft versus-host disease than recipients of BM transplants from HLA-identical siblings. CD34＋ UCB cells are rich fractions in hepatic progenitor cells, and transdifferentiation from UCB cells into hepatocytes and cell fusion simultaneously occur (37). In a primary culture system supplemented with growth/ differentiation factors, about 50% of UCB cells in 21-day cultures express ALB, and ALB＋ cells co express hepatocyte lineage markers. ALB-expressing cells are able to proliferate in the culture system. In the cell transplantation model of liver-injured SCID mice, inoculated UCB cells develop into functional hepatocytes in the liver, which release human ALB into the sera of the recipient mice. Thus, human UCB is a source of transplantable hepatic progenitor cells (38).
It was reported that human UCB cells can migrate into NOD-SCID liver and become mature hepatocytes. No cell S TEM CELLS have been a focus in life science studies. [1] [2] [3] [4] Recent studies have shown that mice and human bone marrow stem cells can differentiate into hepatocytes in normal livers. Furthermore, rat bone marrow stem cells turned into hepatocytes in severely damaged livers with suppression of hepatocyte proliferation. [5] [6] [7] [8] [9] Hepatic fibrosis is a common pathological consequence of various chronic liver diseases. It has not been known whether HSC can differentiate into hepatocytes in liver fibrosis. In the present experiment, we studied the differentiation of rat HSC in a model of established liver fibrosis.
MATERIALS AND METHODS Animals
Male Sprague-Dawley rats weighing 170 to 190 g were obtained from Academy of Military Medical Science. They were bred and maintained on standard laboratory chow using 12-hour light/dark cycles. The studies met the national guidelines for animal usage in research.
Induction of Hepatic Fibrogenesis
Rat liver fibrosis was induced using subcutaneous injection of 40% CCl 4 dissolved in olive oil, twice a week for 6 weeks, as previously described. 10 Thy ϩ CD3 Ϫ CD45RA Ϫ HSC Enrichment After the last CCl 4 injection, the rats were anesthetized using an intraperitioneal injection of sodium pentobarbital (30 mg/kg body weight). Under general anesthesia, bone marrow was aspirated from a tibia with a syringe containing 1 mL heparin with an 18-gauge needle. The marrow cells, transferred to a sterile tube, were mixed with 10 mL culture medium (RPM1640 with 10% fetal bovine serum, penicillin G100u/mL, and streptomycin 100 ug/mL). Red blood cells in bone marrow were depleted using erythrolysin. After three times washing with phosphate-buffered saline (PBS), the cells were incubated at 4°C for 30 minutes with fluorescein isothiocyanate (FITC)-conjugated anti-Thy mAb (Pharmingen), phycoerythrin (PE)-conjugated anti-CD3 mAb (Becton Dickinson), or PE-conjugated anti-CD45RA mAb. Cells washed three times were resuspended in medium. Labeled cells were analyzed and separated with the FASC-vantage apparatus (Becton Dickinson, San Jose, Calif). Gating was based on Thy-positive, CD3negative, and CD45RA-negative. marrow stem cells differentiated into hepatocytes in the hepatic fibrogenesis environment. The PKH26-GL-labeling and Alb-expressing cells were 0.17 Ϯ 0.02% among all hepatocytes.
Immunofluorescence Method for ␣-SMA
We found that myofibroblasts in fibrotic liver sections were positive for ␣-SMA ( Fig 5A) . PKH26-GL-labeled cells in the fibrotic liver did not express ␣-SMA ( Fig 5) . The result indicated that bone marrow stem cells did not differentiate into myofibroblasts in the hepatic fibrogenesis environment.
DISCUSSION
A variety of chronic injuries of hepatocytes caused by viral hepatitis, alcohol abuse, drugs, autoimmune attack and metabolic diseases due to overload of iron or copper may lead to hepatic fibrosis. 11 An animal model of liver fibrosis in the rat is commonly induced by repeat subcutaneous injection of CCl 4 . Liver fibrosis degrees are judged by serum markers, tissue collagen content, and pathologic examination. Liver tissue pathology examination is the gold standard of hepatic fibrosis diagnosis. 12 In our study, the results of liver tissue VG staining showed that subcutaneous injection of CCl4 induced liver fibrosis in the rat.
Stem cells are generally defined as elements capable of both self-renewal and multilineage differentiation. 13, 14 The earliest stem cells in ontogeny are totipotent, extending from the zygote to the inner cell mass of the blastocys. Soon thereafter, totipotent stem cells give rise to somatic stem/ progenitor cells and primitive germline stem cells. 14 Re-cently, stem cells have been identified in adult tissues, such as the hematopoietic, intestinal, neural, and epidermal systems. Studies on bone marrow transplantation showed that bone marrow stem cells can differentiate into multilineage cells, such as cardiac muscle cells, nerve cells, and hepatocytes. [15] [16] [17] By transplanting male mouse bone marrow cells into lethally irradiated female recipients and following the fate of syngeneic cells using fluorescence in situ hybridization of Y chromosome and hepatocyte maker. Theise observed cells positive for the Y chromosome in recipient mouse liver that expressed hepatocyte makers. 5 The results suggested that bone marrow stem cells could differentiate into hepatocytes in the normal liver environment. Bone marrow transplantation in human has also confirmed this result. 7 Petersen reported that normal male rat bone marrow cells were transplanted into female rats with hepatic injury that inhibited hepatocyte proliferation. 18 Donor cells in the recipient liver expressed hepatocyte markers. 18 Lagasse found that bone marrow cells differentiate into hepatocytes in fumarylacetoacetate hydrolase-deficient mouse liver. 8 The two experiments above suggested that bone marrow stem cells differentiated into hepatocytes in some liver pathologic environments. By enriching, labeling, and autotransplanting HSC into rats with hepatic fibrogeneration, we showed that labeled cells in the fibrotic liver express Alb and CK8 hepatocyte markers. We confirmed that HSC differentiated into hepatocytes in hepatic fibrogenetic environment.
The normal liver contains hepatocytes, endothelioctyes, Kupffer cells, and hepatic stellate cells. Hepatic stellate cells are the key fibrogenic cells. 19 During hepatic fibrogenesis, Immunofluorescence method for ␣-SMA on frozen liver tissue section from CCl 4 -treated rats. a, b, c: the same section under confocal microscopy at different wavelengths. Myofibroblasts express ␣-SMA (green cells, a). There were sporadic PKH26-GL labeled cells (red cells. b). PKH26-GL labeled cells did not express ␣-smooth muscle actin (red cells, c). 
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ZHAN, WANG, WEI ET AL hepatic stellate cells undergo a response known as "activation," which is the transition of quiescent cells into myofibroblasts. Activated hepatic stellate cells are the critical source of extracellular matrix in hepatic fibrosis. 20, 21 Quiescent hepatic stellate cells do not express ␣-SMA, but myofibroblasts express ␣-SMA, and ␣-SMA have been considered the marker of myofibroblasts. 22, 23 The recent reports have shown that rat neural crest stem cells can differentiate into myofibroblasts that express ␣-SMA and mouse bone marrow can differentiate into myofibroblasts in peritoneal granulation tissue. 24, 25 Can bone marrow stem cells differentiate into myofibroblasts in hepatic fibrogenesis? Our results showed that bone marrow stem cells did not differentiate into myofibroblasts in a hepatic fibrogenesis environment.
In conclusion, we observed that bone marrow stem cells differentiated into hepatocytes, but not into myofibroblasts, the key cells for liver fibrosis in a hepatic fibrogenesis environment. The result suggested that autologous transplantation of stem cells may be helpful for the treatment of chronic hepatitis and hepatic fibrosis. tation of bone marrow cells improves damaged heart function.
Circulation Widespread use of liver transplantation in the treatment of hepatic diseases is restricted by the limited availability of donated organs. One potential solution to this problem would be isolation and propagation of liver progenitor cells or stem cells. Here, we report on the isolation of a novel progenitor cell population from unmanipulated (that is, no prior exposure to chemicals and no injury) adult rat liver. Rat liver cells were cultured following a protocol developed in our laboratory to generate a unique progenitor cell population called liver-derived progenitor cells (LDPCs). LDPCs were analyzed by fluorescence-activated cell sorting, real-time polymerase chain reaction (RT-PCR), immunostaining and microarray gene expression. LDPCs were also differentiated into hepatocytes and biliary epithelium in vitro and examined for mature hepatic markers and urea and albumin production. These analyses showed that, LDPCs expressed stem cell markers such as cluster domain (CD)45, CD34, c-kit, and Thy 1, similar to hematopoietic stem cells, as well as endodermal/hepatic markers such as hepatocyte nuclear factor (HNF)3␤, hematopoietically-expressed homeobox gene-1, c-met, and transthyretin. LDPCs were negative for OV-6, cytokeratins (CKs), albumin, and HNF1␣. The microarray gene expression profile demonstrated that they showed some similarities to known liver progenitor/stem cells such as oval cells. In addition, LDPCs differentiated into functional hepatocytes in vitro as shown by albumin expression and urea production. In conclusion, LDPCs are a population of unique liver progenitors that can be generated from unmanipulated adult liver, which makes them potentially useful for clinical applications, especially for cell transplantation in the treatment of liver diseases. Diseases of the liver are common causes of morbidity and mortality in the world. 1 Despite the high incidence of liver diseases that result in liver dysfunction and failure, current medical therapies are limited to supportive care, rather than curative approaches, with the possible exception of liver transplantation. Liver transplantation is considered to be the standard treatment for end-stage liver disease. 2 Unfortunately, its extensive application is restricted by the limited availability of donor organs. In addition, liver trans-plantation is associated with significant morbidity and mortality. As most liver disorders result from hepatocyte dysfunction, there has been great interest in transplantation of isolated hepatocytes. However, their clinical application is also dependent on the availability of good quality donor livers.
To overcome the problem of limited donor organs and to make hepatocytes available for other applications, several approaches to isolate and propagate liver stem cells or progenitor cells have been developed. 3, 4 It is Abstract The liver has adapted to the inflow of ingested toxins by the evolutionary development of unique regenerative properties and responds to injury or tissue loss by the rapid division of mature cells. Proliferation of the parenchymal cells, i.e. hepatocytes and epithelial cells of the bile duct, is regulated by numerous cytokine/growth-factormediated pathways and is synchronised with extracellular matrix degradation and restoration of the vasculature. Resident hepatic stem/progenitor cells have also been identified in small numbers in normal liver and implicated in liver tissue repair. Their putative role in the physiology, pathophysiology and therapy of the liver, however, is not yet precisely known. Hepatic stem/progenitor cells also known as "oval cells" in rodents have been implicated in liver tissue repair, at a time when the capacity for hepatocyte and bile duct replication is exhausted or experimentally inhibited (facultative stem/progenitor cell pool). Although much more has to be learned about the role of stem/progenitor cells in the physiology and pathophysiology of the liver, experimental analysis of the therapeutic value of these cells has been initiated. Transplantation of hepatic stem/progenitor cells or in vivo pharmacological activation of the pool of hepatic stem cells may provide novel modalities for the therapy of liver diseases. In addition, extrahepatic stem cells (e.g. bone marrow cells) are being investigated for their contribution to liver regeneration. Hepatic progenitor cells derived from embryonic stem cells are included in this review, which also discusses future perspectives of stem cell-based therapies for liver diseases.
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Stem cells in liver regeneration
Physiological homeostasis of the liver Under physiological conditions, as few as one out of 2000-3000 hepatocytes divide to maintain the physiological liver mass. Liver damage or loss of liver mass can however extensively stimulate the regenerative capacity until the tissue mass has been restored by the proliferation of mature parenchymal liver cells (Fausto et al. 2006 ). Up to 75% of surgically removed liver mass can be regenerated within 1 week in rodents (Michalopoulos and DeFrances 1997). Accelerated parenchymal regeneration after necrogenic or surgical loss of liver tissue principally originates from the extensive proliferation of mature parenchymal liver cells rather than from liver stem/progenitor cell proliferation. In a young adult rat or mouse, approximately 95% of hepatocytes replicate during the first 3 days after partial hepatectomy. This proportion drops to approximately 80% in senescent rats (Tsanev 1975) .
The newborn liver contains only diploid hepatocytes but polyploidisation and binuclearity occurs rapidly after birth. Fractionation of isolated adult rat hepatocytes based on cell density has yielded subpopulations with "small" mononucleated hepatocytes and "large" hepatocytes with higher ploidy. Hepatocytes with higher ploidy have been shown to reside predominantly in the perivenous areas and to contain more DNA and to exhibit greater maturity. The "smaller" mononucleated hepatocytes are located in the periportal areas, contain less DNA and exhibit greater growth factor responsiveness. The gradient of less complex cells with higher proliferation potential (in vitro) in periportal areas and more mature hepatocytes in perivenous areas has been interpreted as evidence for the existence of a physiological stem cell compartment (Sigal et al. 1995). The "streaming liver hypothesis", which suggests that the liver lobule is organised in a similar way to the intestinal crypt by containing a stem cell pool arising form the periportal area has, however, been disproved by the observation that nearly all hepatocytes proliferate as a response to injury, regardless of location and ploidy.
Although mature hepatocytes and cholangiocytes represent the first and most important resource for tissue repair, experimental data support the hypothesis that the liver also contains or activates a stem cell compartment ( 
Resident hepatic stem/progenitor cells
Evidence for the existence and activation of a resident hepatic stem/progenitor cells (rHSPC) compartment has been provided from various murine animal models of "oval cell" proliferation (Alison et al. 1997; Fausto 2004; Thorgeirsson 1996) . The general principle underlying oval cell activation is based on a combination of liver injury and the inability of hepatocytes to proliferate in response to damage. For example, if a DNA-damaging agent is administered followed by partial hepatectomy, mitosis of hepatocytes is blocked, and oval-shaped cells emerge from the portal zone. These oval cells play a facultative role in liver regeneration, i.e. they contribute to tissue regeneration only in cases in which adult hepatocyte proliferation is inhibited or exhausted (Fausto and Campbell 2003) .
A cell compartment that has not as yet been defined gives rise to these rapid proliferating transient cells that subsequently differentiate into mature hepatocytes and bile duct cells. Anatomically, they arise from areas close to the terminal biliary duct (canals of Hering) of the liver, although additional locations have been described. To date, whether oval cells pre-exist in the tissue or develop from other adult cell types (i.e. bile duct cells) after an injury, is unknown. The restricted potential to differentiate into hepatocytes and cholangiocytes qualifies oval cells more as progenitor cells rather than true stem cells. Cell lines with "non-hepatocyte" phenotypes, which can function as lineage-generating precursors, have been derived from livers of rodents exposed to toxic chemicals or carcinogens and from normal liver with no histological evidence of stem/progenitor cell activation The dissection and classification of cell populations on the basis of their molecular heterogeneity have become fundamental working tools in cell biology. For example, the differentiation state, lineage specificity or functional status of a given haematopoietic cell population can be precisely determined and communicated based on their antigenic and molecular properties (Mason et al. 2002) . In contrast to the haematopoietic cell lineage, the molecular characterisation of the stem cell compartments in solid organs still suffers from the lack of specific markers that unambiguously label all stem cells and only stem cells, enabling their prospective identification, cultivation and propagation. For a long time, this absence of tissue-specific stem cell markers has posed challenges to the identification and isolation of the "true" liver stem cell. A systematic understanding of the stem cell compartment and their respective cell lineages, however, is of fundamental importance for our understanding of physiological liver regeneration and liver tissue repair after injury and disease. A range of markers has been used to characterise the rHSPC compartment including a host of monoclonal antibodies against cytoskeletal proteins and unknown surface antigens. However, few appropriate cell surface markers that permit the fractionation of viable liver For this reason, the stem/progenitor compartment of the liver is assumed to consist of cells with various phenotypes and multiple molecular markers. Most of the markers have been identified by immunohistochemistry from rodent models of oval cell activation. In multiple independent studies, these oval cells have been shown to share molecular markers with adult hepatocytes (albumin, cytokeratins 8 and 18), bile duct cells (cytokeratins 7 and 19, OV-6, A6), fetal hepatoblasts (AFP), and haematopoietic stem cells (Thy -1, Sca-1, c-kit). In a recently published mouse model with transgenic expression of the green fluorescence protein (GFP) under transcriptional control of nestin gene promoter and enhancer elements, Gleiberman and co-workers (2005) have identified, in the normal liver, GFP-marked cells at low frequencies with characteristic properties of oval cells, indicating a pre-formed stem/progenitor cell pool in the liver. Additional molecular markers have been identified by genome-wide analysis of mRNA expression in liver tissue and cells derived from rodent injury models with oval cell activation.
Such studies are beginning to elucidate the molecular markers and signalling pathways involved in stem cell/
Introduction
Primary cultures of hepatocytes represent an experimental tool that has been used extensively in biomedical research, both in academia as well as for commercial purposes such as drug development. The most exciting advances are the successful isolation, culturing, and cryopreservation of hepatocytes from human livers. 
Human hepatocyte isolation
One of the major advances in human hepatocyte technology is the availability of human livers for research. In the United States, livers procured but not used for transplantation are allowed to be used in research. The major reasons that procured livers are not used for transplantation are as follows:
1. unavailability of a matched recipient; 2. physical damage to the liver; 3. pre-existing liver diseases; 4. breach of sterility during the procurement process; 5. high liver fat content; 6. inappropriate age (too young or too old); 7. inappropriate warm ischemic time; 8. inappropriate cold storage time.
Livers that are procured for transplantation are usually flushed extensively with a cold preservation solution, with the University of Wisconsin (UW) or histidine-tryptophan-ketoglutarate (HTK) solutions being the most common [1] . The rule of thumb is that viable hepatocytes can be obtained from human livers with up to 24 h of cold preservation. There are, however, cases that highly viable hepatocytes can be obtained from livers stored beyond this 24-h period.
Hepatocyte isolation from human livers is now universally performed with a "two-step" collagenase procedure developed by Berry and Friend [2] . Originally developed for the isolation of rat hepatocytes, this procedure has been modified by various laboratories for the isolation of hepatocytes from sevreal animal species, including human (e.g. [3, 4] ). The procedure involves the initial perfusion of the liver with a warm (37 • C) divalent ion-free, EGTA-containing, isotonic buffer (Step 1) to remove blood and to loosen cell-cell junctions, followed by perfusion with a warm, isotonic, collagenase solution (Step 2) to dissociate the liver parenchyma into single cells. In general, a higher amount of collagenase is required for the isolation of hepatocytes from human livers than that required for rat livers. As collagenase is a mixture of proteases, its composition can affect its effectiveness in the dissociation of the hepatocytes as well as its cytotoxicity. It is a common practice to evaluate multiple lots of collagenase to select the one lot yielding the highest number of viable hepatocytes from a liver. After digestion, the cells are harvested by lowspeed centrifugation. A density gradient such as Percoll is commonly used to enrich for viable cells. The isolated cells can be used in suspension for experiments requiring a relatively short time duration (hours), plated on tissue culture surfaces pretreated with attachment substrates (e.g. collagen; Matrigel) for longer term studies, or cryopreserved for future use.
The method of isolation of human hepatocytes from a human liver is by no means optimized. Currently, a socalled "good" yield of human hepatocytes from a human liver is approximately 10-30 billion viable cells when a whole liver is perfused. Using an approximation of 1.5 kg as an average weight of a human liver, this leads to a yield of or approximately 7-20 million hepatocytes per gram of liver (e.g. [5, 6] ), which is considerably less that the total number of hepatocytes (approximately 300 billion) in the human liver. It is to be noted that the yield of human hepatocytes (in terms of number of hepatocytes per gram liver) is in general higher from smaller (e.g., 10 to 300 g) liver fragments then whole livers or lobes.
Cryopreservation
Hepatocytes, especially human hepatocytes, are now routinely used after they are cryopreserved [7, 8] . The general procedures for hepatocyte cryopreservation have not deviated extensively from the original procedures [9] . Via the use of equipments to control freezing rates (e.g. programmable control-rate freezer) and appropriate cryopreservation agents (e.g. dimethyl sulfoxide), hepatocytes now can be stored in liquid nitrogen (lower than −150 • C) for an extensively time period (years) with the retention of high viability and drug metabolizing enzyme activity [7] . The most recent advancement of human hepatocyte cryopreservation is the ability of the thawed hepatocytes to be plated as monolayer cultures ("plateable" hepatocytes) [10, 11] . In our laboratory, we routinely prepare cryopreserved human hepatocytes with most of the lots having post-thaw viability of >90% (Table 1) and with approximately half of the lots yielding over 50% confluent monolayer cultures when plated onto collagen-coated plates ( Table 1 ; Fig. 1 ). In our laboratory, we believe that the key to successful cryopreservation is to ensure that the hepatocytes are isolated from the human liver with minimal damages to the plasma membrane.
It is important to fully understand the properties of cryopreserved human hepatocytes as compared to freshly isolated cells. The following are general conclusions on the drug metabolizing enzyme activities of cryopreserved human hepatocytes: 
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Preliminary experience with clinical hepatocyte transplantation during the past decade has provided proof of concept that cell therapy can be effective for the treatment of some liver diseases. Recent progress in cell biology resulting in the isolation and characterization of hepatic stem cells and progenitor cells further increased the expectation for a new approach to the treatment of genetic and chronic liver disease. Several potential sources have been identified of hepatic stem/ progenitor cells exhibiting both differentiation towards the hepatic lineage in vitro and hepatic parenchymal repopulation with liver-specific metabolic activity in liver-injured animal models. However, a few of these results proved to be poorly reproducible in different laboratories, and it was recognized that some initial optimistic conclusions were drawn from incorrect interpretation of experimental data or from insufficient knowledge of the mechanisms involved in tissue regeneration. Moreover, only modest results have emerged so far from ongoing clinical experience involving the use of putative stem cells in liver disease.
There is much need for a joined effort to concentrate the resources on a specific cell population, in order to better characterize its function, to assess its safety and to develop better focused clinical trials. In conclusion, while the biological features of stem cells still justify the hope for future clinical applications, hepatic stem cell therapy has still a long way to go from bench to bedside.
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Cell therapy can be defined as «the use of living cells to restore, maintain or enhance the function of tissues and organs». 1 The use of isolated, viable cells has emerged as an experimental therapeutic tool in the past decade, due to progress in cell biology and particularly in techniques for the isolation and culture of cells derived from several organs and tissues. However, experimental cell therapy has a longer tradition in Hepatology, since it has been known for more than 30 years that isolated hepatocytes infused into the portal vein engraft into the liver cords and express normal cell function. Such a therapeutic strategy was put forward as an alternative to orthotopic liver transplantation (OLT), which requires major surgery and is limited by the availability of donors. Indeed, it was shown that significant clinical results can be obtained with the transplantation of isolated hepatocytes corresponding to as little as 1-5% of the total hepatocyte mass. [2] [3] [4] [5] [6] The procedure seems relatively safe, provided portal pressure and/or portal flow are monitored during cell infusion in order to prevent vascular thrombosis. 7 Hepatocyte transplantation has recently been used as an alternative to OLT in patients with liver-based congenital metabolic disorders, such as Crigler-Najjar disease, 8 α-1-antitrypsin deficiency, 9 glycogen storage disease type Ia, 10 ornithine transcarbamoylase deficiency 11, 12 and the deficiency of factor VII. 13 The role of hepatocyte transplantation in the treatment of acute and chronic liver disease is less clear, 9, 14 due to difficulty in organizing large-scale clinical trials. Indeed, the main factor limiting the practice of hepatocyte transplantation is again the availability of liver grafts for cell isolation. Moreover, the metabolic effects of cell transplantation seem to be fading with time, a problem which can partially be solved by repeated hepatocyte infusions 15 but which probably indicates the progressive loss of the terminally-differentiated exogenous cells. In theory, both problems could be solved by replacing the hepatocyte with Indeed, at present, there is growing interest in the therapeutic use of stem cells. 16, 17 A stem cell has the ability to divide for indefinite periods of time, to self-renew and to give rise to many different cell types. Embryonic stem cells originate from the inner cell mass of the mammalian blastocyst and are totipotent. 18 Adult stem cells are more specialized, being committed to give rise to cells with a particular function within their own specific tissue or organ. 19 Precursor/progenitor cells are defined as cells rapidly dividing and already partially determined towards a specific differentiation pathways. 20 However, experimental evidence suggests that some adult stem cells are able to develop into different types of specialized cells (a process also known as transdifferentiation), depending on the microenvironment where they are homed, including the liver. 19, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] This review will address a series of major issues on hepatic stem cells, including their origin, their role in liver regeneration and fibrosis, and their possible use in the treatment of liver disease.
What is the origin and what are the possible sources of hepatic stem cells?
In mammals, the liver has the unique ability among solid organs to regenerate following parenchymal injury. During fetal development, hepatoblasts give rise both to hepatocytes and to cholangiocytes. The hepatocyte is traditionally considered as the cell responsible for liver regeneration, being able to re-enter the cell cycle, proliferate and differentiate both into hepatocytic and biliary lineage in response to loss of liver mass. However, an intra-hepatic progenitor cell compartment, resident in the canals of Hering and consisting of precursors known as «oval cells» in rodents (or «hepatic progenitor cells» in human), is activated when the replicative capacity of the main epithelial cell compartment is inhibited or exhausted. [31] [32] [33] [34] [35] [36] These small round cells express phenotypic markers of both fetal hepatocytes and biliary cells 35,37-39 and are able to differentiate into hepatocytes, bile ductural cells and intestinal epithelium. 40 SHPCs also appear to be involved in the process of hepatic regeneration. SHPCs are highly proliferative and can generate mature differentiated hepatocytes in vitro. 41, 42 SHPCs express markers such as albumin, alpha-fetoprotein, transferrin, form bile canaliculi and store glycogen. 43 SHPCs also appear to be involved in the process of hepatic regeneration after partial hepatectomy (PH) in rats pre-treated with retrorsine, a pirrolyzidine alkaloid which severely impairs the proliferating capacity of mature hepatocytes. 41, 44, 45 In this model, hepatic repopulation takes place mainly by proliferation of SHPCs, exhibiting phenotypic traits in common with fully differentiated hepatocytes, fetal hepatoblast, and oval cells. 46 Some reports suggest that SHPCs don't originate from oval cells, 42 but that they derive from a pre-existing population of retrorsine-resistant hepatocytes. 47 Indeed, during liver regeneration, the SHPCs lack hepatic cytocrome P450 protein 48 that is responsible for metabolizing retrorsine to pyrrolic derivatives 49 and are thus resistant to the toxic effect of the drug. Avril et al. 47 labeled mature hepatocytes using a recombinant retroviral vector harboring the β-galactosydase "LacZ" gene in the retrorsine/PH rat model. During parenchymal regeneration, a similar (4%) proportion of β-galactosydase-positive SHPCs and of mature hepatocytes was observed, suggesting that mature hepatocytes could be the actual progenitors of SHPCs. 47 However, more recently, using 3-dimensional image analysis in the retrorsine/PH model of liver regeneration, Vig et al. observed that oval cells surround and penetrate SHPCs nodules, suggesting that SHPCs nodules can originate from oval cells. 43 The origin of hepatic stem or precursor cells is still a matter of debate. Interestingly, oval cells express markers of Hematopoietic Stem Cells (HSCs), such as Thy-1, CD34, CD45, Sca-1, c-Kit and flt-3. 22, [50] [51] [52] [53] [54] In particular, Thy-1 is a highly conserved protein. It has been found in the brain and in the hematopoietic system of rat, mouse and humans. 53 It is also expressed on stem cells of fetal liver and in bone marrow (BM)-derived cells. 55 In addition, the normal adult liver contains hematopoietic cells that are phenotypically similar to cells present in the BM. 56 These observations originated the hypothesis that liver stem cells may arise from a population resident in the BM. 22 Petersen et al. 22 followed the fate of syngeneic BM cells transplanted into lethally irradiated rats whose livers were subsequently injured by 2-acetylaminofluorene and CCl 4 , a regimen known to induce oval cell proliferation. Using the sry gene as a marker for the Y chromosome, male donor cells were visualized in female recipients. In a separate experiment, didpeptidyl peptidase IV (DPP IV)-positive hepatocytes were identified in the liver of DPP IV -deficient rats transplanted with BM from DPP IV-positive animals.
Lagasse et al., 29 transplanted fumarylacetoacetate hydrolase (FAH)-deficient mouse, an animal model of Tyrosinemia type I, with BM cells from a non-affected wildtype animal transgenic for the β-galactosidase "LacZ" gene. The liver of the recipient animals was progressively repopulated with hepatocytes harboring both the β-galactosidase and the fumarylacetoacetate hydrolase enzyme. Thus, intravenous injection of adult BM cells in the FAH-/-mouse rescued the mouse and restored the biochemical function of its liver. It was later shown that the correction of the metabolic disorder was not due to transdifferentiation of HSCs but rather to a fusion process, probably involving macrophages derived from the exogenous hematopoietic cell lineage and the recipient hepatocytes. 57, 58 This phenomenon can be demonstrated by cytogenetic analysis in sex-discordant transplantation (Figure 1) .
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times, these Authors showed that the MSCs acquired hepatocyte morphology and expressed genes and functions characteristic of liver parenchymal cells. A modified differentiation medium, containing FGF-4, Oncostatin M, HGF and EGF, was used by Shi et al., to induce BM-derived mononuclear cells of C57BL/6 mice to differentiate into hepatocyte-like cells. 62 However, in contrast to the above results indicating that oval cells may be derived from the BM, recent work suggests that such cells originate in the liver itself. 43, 57, 63 In summary, experimental evidence suggests that liver parenchymal cells can originate from a specific precursor cell compartment in the liver, from pluripotent stem cells, from transdifferentiation of HSCs or from cell fusion. The occurrence of true transdifferentiation, or reprogramming to the hepatic lineage of an already committed hematopoietic stem cell, is still a matter of debate. 30 Additional, potential sources of hepatic stem cells have been identified in the cord blood, in the amniotic fluid and in the placenta. Umbilical Cord Blood (UCB) contains hematopoietic and mesenchymal stem/precursor cells Lee et-al. 64, 65 The transplantation of UCB has been used for more than 10 years for the treatment of hematologic and genetic diseases. 66-71 UCB cells are easily accessible, proliferate in vitro and have longer telomeres compared to adult cells, indicating higher proliferation capacity. 72-74 Several Authors have investigated the hepatic potential of UCB-derived cells in vitro and in vivo. Kakinuma et al., 75 showed that human UCB cells cultured in the presence of a particular combination of growth and differentiation factors (i.e. FGF-1, FGF-2, LIF, SCF and HGF) were able to produce albumin and other hepatocytes specific markers in vitro. When inoculated into liver-injured SCID mice, a few functionally differentiated human UCB-derived hepatocytes were found 55 weeks post transplantation. By means of a «two-step» differentiation medium, Lee et al., 65 induced human UCB-derived (CD3 -, CD14 -, CD19 -, CD38 -, DC66b -, glycophorin A -) MSCs to differentiate into hepatocyte-like cells. Sharma et al., 76 reported that human UCB-derived mononuclear cells generate hepatocyte-like cells after transplantation into NOD-SCID mice with severe hepatocellular damage produced by CCl 4 . Noteworthy, all such cells showed some specific human hepatic markers but not a mature hepatocyte phenotype. Moreover, all the donorderived hepatic cells expressed human albumin and human hepatocyte-specific antigen Hep Par 1 but also expressed the murine cytokeratine CK18, suggesting the occurrence of fusion between human and mouse cells. Newsome et al., 77 infused an unsorted UCB mononuclear cell preparation into sub-lethally irradiated NOD-SCID mice. These cells were able to engraft into mice livers and differentiate into hepatocytic lineage with no evidence of fusion with mouse hepatocytes. 77 Piscaglia et al., 78 transplanted into immunocompetent rats a CD34 + / CD45 + and CD133 + /CD45 + population from human A. Differentiation of BM-derived cells into liver parenchymal cells originates hepatocytes with the same chromosomal pattern as the parent stem cell (XY), and such identity is maintained also in the case of polyploidy, which is common in the liver (e.g. XYXY in tetraploid cells). B. By contrast, cell fusion between male hematopoietic cell lineage (XY) and female hepatocytes (XX) results in a XXXY pattern, as it was shown in the Lagasse model. 58 
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liminary evidence of therapeutic effectiveness has been provided in animal models. However, we have to learn more on the mechanisms of liver regeneration, including the role of stem/precursor cells. Definite (and possibly joined) protocols for the selection of a specific cell population and for in vitro expansion/differentiation should be developed, as well as protocols for clinical liver repopulation. The long-term fate of the transplanted cells should also be assessed in animal models, with respect to function, possible extra-hepatic localization, genetic/epigenetic stability and especially tumorigenesis. The risk is that superficial planning, without adequate consideration and knowledge of the underlying pathophysiology, will result in poorly focused clinical trials and possible complications, which could in turn originate skepticism on the development of cell therapy in Hepatology. Even if the biological characteristics of hepatic stem cells still justify the hope for successful future clinical applications, only a more cautious and systematic «bench to bedside» approach will guarantee consistent results.
Abstract
Research involving differentiated embryonic stem (ES) cells may revolutionize the study of liver disease, improve the drug discovery process, and assist in the development of stem-cell-based clinical therapies. Generation of ES cell-derived hepatic tissue has benefited from an understanding of the cytokines, growth factors and biochemical compounds that are essential in liver development, and this knowledge has been used to mimic some aspects of embryonic development in vitro. Although great progress has been made in differentiating human ES cells into liver cells, current protocols have not yet produced cells with the phenotype of a mature hepatocyte. There is a Biotechnology and Genetic Engineering Reviews -Vol. 25, 149-164 (2008) To whom correspondence should be addressed (foxi@upmc.edu) Care must be taken when evaluating studies describing the extent to which mature liver cells have been successfully derived from stem cells. Stem cell-derived "hepatocytes" have been generated using many strategies, and have been shown to secrete albumin and urea, and express cytochrome P450 (CYP) enzyme activity. However, a more detailed analysis of gene expression, metabolic activity, growth potential, and secretory function will be required to determine whether such cells can fully function as primary hepatocytes (Nahmias et al., 2007; Runge et al., 2000) (Figure 1) . 
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Mammalian liver development and its relationship to stem cell differentiation
EARLY GASTRULATION AND FORMATION OF DEFINITIVE ENDODERM
Embryonic stem cells are derived from the undifferentiated cells of the epiblast, which give rise to the three principal germ layers and their differentiated progeny through a process called gastrulation (Wells and Melton, 1999). Of the three germ cell layers, the endoderm gives rise to hepatic, pancreatic, lung, and intestinal tissues in a process that is not well understood. The transcription factors orthodenticle homeobox 2 (Otx2), HESX homeobox 1 (Hesx1), homeobox Hex, and caudal-related homeobox 2 (Cdx2) are associated with formation of definitive endoderm and are expressed prior to activation of organ specific genes (Wells and Melton, 1999). Genes critical for cellfate determination emerge from the mesendoderm shortly thereafter. Among these are goosecoid (GSC) forkhead box A2 (Foxa 2), chemokine C-X-C motif receptor 4 (CXCR4), sex determining region-Y box 17 (Sox17a/b), brachyury, E-cadherin, vascular endothelial growth factor receptor-2 (VEGFR2), VE-cadherin, platelet-derived growth factor receptor-a (PDGFRa), and GATA binding protein 4, (GATA-4) (Yasu-Downloaded by [188. 26.20 .200] at 03: 32 13 December 2017 32 13 December naga et al., 2005 . An appreciation of the genetic patterns and cellular markers that distinguish definitive endoderm from extraembryonic endoderm, such as EpCAM, CD38, and DPPIV, have been critically important in the process of differentiating and isolating tissue-specific cells from stem cells (Sherwood et al., 2007) .
Definitive endoderm can be generated by a variety of means. Definitive endoderm can be produced through formation of embryoid bodies or by culturing ES cells with collagen-sandwiched hepatocytes (Cho et al., 2007) . Large numbers of endoderm like-cells can also be produced when mouse ES cells are cultured on fibronectin-coated collagen gels and exposed to follistatin, an Activin binding protein (Parashurama et al., 2007) . The common transcriptional machinery present in both definitive and visceral endoderm may, however, limit the extent to which differentiation using these techniques can lead to tissue formation. Generation of a pure population of definitive endoderm from ES cells may require selective inhibition of visceral endoderm.
Recently 
HEPATIC INDUCTION
Growth factor signaling from the cardiac mesoderm and septum transversum mesenchyme specifies the underlying endoderm to adopt a hepatic fate such that, by the 6-7 somite stage, hepatic gene expression can be detected in the ventral foregut endoderm (Jung et al., 1999; Rossi, 2001) . Using a variety of techniques, it has now been shown that fibroblast growth factors (FGFs) can substitute for cardiac mesoderm and bone morphogenic proteins (BMPs) can substitute for the septum transversum mesenchyme to work in concert to induce the ventral endoderm to adopt a hepatic fate (Jung et al., 1999) . Studies documenting induction of hepatic specification following chick cardiac mesoderm co-culture with ES cells, or following culture in FGF and BMP, illustrate how such developmental principles can assist with stem cell differentiation in vitro (Cai et al., 2007; Fair et al., 2003; Gouon-Evans et al., 2006; Soto-Gutierrez et al., 2007) . Factors identified as proposed targets of FGF and BMP signaling include the Foxa and Gata genes, which regulate the competence of foregut endoderm to respond to hepatic inductive signals (Cirillo et al., 2002) . In addition, the transcription factor hepatocyte nuclear factor-6 (HNF6) has been shown to play a critical role in the proper morphogenesis of both the intra-and extra-hepatic biliary tree. The mechanism by which HNF6 regulates biliary tree development also appears to involve the related transcription factor, hepatocyte nuclear factor-1 (HNF1) (Clotman et al., 2005) ( Figure 2) . LIVER , 2004) . While Notch inhibits differentiation to hepatocytes, HGF induces expression of C/EBPα in albumin-negative fetal liver cells. When C/ EBPα activity is blocked, there is no transition from the albumin-negative to the albumin-positive stage. HGF promotes differentiation of albumin-positive cells from albumin-negative precursors, but inhibits further differentiation of albumin-positive cells into biliary cells, suggesting that HGF promotes the establishment of a bipotent state in hepatoblasts (Suzuki et al., 2002) . Thus, TGFß, HGF, C/EBPα, and HNF6, in combination with Notch, work in concert to form a network of signals that controls bipotency and allows later biliary or hepatocyte differentiation.
The crucial early budding phase of liver development involves hepatic interaction with endothelial cells (Cleaver and Melton, 2003; Matsumoto et al., 2001) and results in hepatoblast proliferation. The mesenchymal cells of the liver, derived from the septum transversum mesenchyme, are essential for this proliferation process to take place (Gualdi et al., 1996) . This requirement for endothelial cells in hepatic endoderm growth has been recapitulated using embryo tissue explants, and appears to persist in the adult liver (Bhatia et al., 1999) . Hepatocyte growth factor (HGF) signaling also controls proliferation in the fetal liver (Uehara et al., 1995) . Finally, the transcription factors Foxm1b and Xbp1 are also required for liver bud cell proliferation. Spontaneous differentiation involves formation of EBs, plating of ES cells on an adherent matrix as a monolayer, or following transplantation into an hepatic envi- ronment (Lavon et al., 2004; Yamada et al., 2002; Yamamoto et al., 2003) . Directed differentiation usually involves addition of growth factors and cytokines to cells in vitro on extracellular matrices (Cai et al., 2007; Rambhatla et al., 2003; Teratani et al., 2005) . Combinations of these techniques, involving both formation of EBs with expansion in growth factors and/or co-culture with cells supplying additional factors, have also been successful (Cho et al., 2007; Fair et al., 2003; Soto-Gutierrez et al., 2006; Soto-Gutierrez et al., 2007) . In addition, culture in sodium butyrate, a histone deacetylase inhibitor, leads to an increase in the number of cells expressing mature hepatocyte-specific genes.
Selection of hepatocyte-like cells based on the use of liver-specific promoters that drive reporter gene expression has been a relatively successful strategy for selecting a homogeneous population of cells with hepatic characteristics (Lavon et al., 2004) . In the majority of settings, the resultant cells have morphological features similar to those of primary hepatocytes and most of the cells express liver-associated proteins (Rambhatla et al., 2003) . Whether such cells have the functional characteristics of a mature liver cell will require a more comprehensive analysis.
ES cell differentiation: state of the art
Using a modification of the protocol described earlier using Activin A to enrich for definitive endoderm (D'Amour et al., 2005), and using principles from development, Cai et al. reported that later addition of FGF, BMP, and HGF to cultured cells induces expression of hepatic fate genes, and that further culture in Oncostatin M (OSM) and dexamethasone (Dex) leads to significant differentiation to cells with a large number of hepatocyte-like characteristics. Transplantation of such differentiated cells into mice with chemically-induced liver injury resulted in engraftment of a small number of ESderived cells in the liver (Cai et al., 2007) . Culture of ES cells in Activin A followed by treatment with sodium butyrate and HGF has been also shown to generate cells exhibiting morphologic characteristics of hepatocytes, expression of alpha-fetoprotein and albumin, and cytochrome p450 (CYP) metabolic activity (Hay et al., 2007) .
ES cells have also been induced to differentiate into "hepatic-like" cells using other approaches (Cai et al., 2007; Cho et al., 2007; Lavon et al., 2004; Rambhatla et al., 2003; Soto-Gutierrez et al., 2007; Teratani et al., 2005) . Development of cells that express hepatocyte markers, such as AFP, Alb, and CK18, inducible expression of cytochrome P450, and morphologic characteristics of an epithelial phenotype has been reported widely (Cai et al., 2007; Lavon et al., 2004; Rambhatla et al., 2003) . However, useful stem cell-derived hepatocytes will need to not only express the genes found in mature hepatocytes, but the levels of expression will need to be at or near those found in the normal liver. Furthermore, differentiation will need to be lineage specific.
Evidence of protein production will need to be demonstrated to provide verification of gene expression studies, and the metabolic activity of CYP enzymes will be needed to provide definitive evidence of mature hepatic function. While hepatocytes are the only cell that secretes albumin, inferring that any albumin-secreting cell can, by definition, be regarded as a hepatocyte is not justified. Many stem cell-derived "hepatocytes" express albumin but many do not express other genes that would Downloaded by [188. 26.20 .200] at 03: 32 13 December 2017 normally constitute normal hepatocyte function. The same can be said for CYP enzyme activity, as p450 expression is not limited to hepatocytes. Inducible CYP activity has been reported by lung, intestinal epithelial cells, and adipose tissue (Baijal et al., 1997; Yoshinari et al., 2004; Zhang et al., 2003) .
To adequately assess the extent to which in vitro differentiation of stem cells has been effective, it will be important to clearly demonstrate cellular characteristics and activities that can only be performed by primary hepatocytes.
In summary, derived hepatocytes should demonstrate drug metabolism and detoxification activity by both gene expression and function, and they should express the hepatic transport proteins and transcription factors present in mature hepatocytes. They should also, to some degree, secrete albumin and/or produce bile acids, conjugate bilirrubin, metabolize ammonia, and function in animal models of liver dysfunction after transplantation. Finally, differentiated cells should no longer express transcription factors or other genes characteristic of cells of other cell lineages (Figure 3) .
Application of stem cell derived liver cells
The availability of a reliable and homogeneous source of human hepatocytes would be an invaluable tool for liver tissue engineering, for use in cell-based in vitro assays of drug toxicity, for metabolic profiling, for the study of drug-drug interactions, and for use in cell therapy and regenerative medicine (Wobus and Boheler, 2005).
CELL THERAPY
The worldwide shortage of donor organs is likely to increase over the coming decades. As a result, development of alternative methods for treating life-threatening liver disease will become increasingly important. While cell transplantation and other cell-based therapies have great potential for improving the lives of patients with liver failure (Fox et al., 1998; Navarro-Alvarez et al., 2007) , the lack of available donors Downloaded by [188. 26.20 .200] at 03:32 13 December 2017 of disease models have been examined concerning whether stem cells can correct liver disease. It is a bit premature to conclude that hepatocytes can be generated from non-hepatic cells in culture that will be clinically useful. Standard criteria will need to be developed to assess the extent to which human stem cell-derived hepatocytes have been produced.
